# Investigational New Drug application

Source: https://onco.cc/terms/investigational-new-drug-application/  
OnCo record `investigational-new-drug-application` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This application supports a specified investigation or treatment-access use of a drug in the United States. It is separate from permission to market the product.

## Summary

An Investigational New Drug application contains nonclinical, manufacturing and clinical-protocol information for defined investigational use. Becoming effective does not establish that the product benefits a person or is approved for marketing, and a clinical hold can prevent use. A New Drug Application or Biologics License Application instead requests marketing authorization. Submission, acceptance for filing, an application becoming effective and a marketing decision are different events. The applicable route and product version matter.

## Fields

- Kind: Term
- Last checked: 2026-11-11
- Also known as: IND application; Investigational New Drug; investigator IND

## Notes

- For an ordinary new IND, FDA describes a 30-calendar-day period after receipt before an investigation may begin, unless FDA gives earlier notification or imposes a hold. Expanded-access INDs and protocols have route-specific rules; no application number establishes a treatment start date.
- Product identity matters alongside the proposed use. A redesigned cell product or personalised formulation cannot acquire another product's evidence or authorisation merely by sharing a target, ingredient category or platform name. FDA assesses nonclinical, manufacturing and clinical-protocol information for the proposed investigation. Ask whether the cited data and permission actually cover that product version and plan; a supplier's earlier authorisation is not itself permission for a different use.

## Sources

- FDA: Investigational New Drug application: https://www.fda.gov/drugs/types-applications/investigational-new-drug-application-ind
- FDA: new drug applications: https://www.fda.gov/drugs/types-applications/new-drug-application-nda
- FDA: biologics license applications: https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-blas-cber-regulated-products
- FDA: expanded access questions and answers, April 2026: https://www.fda.gov/media/162793/download

## Connected records

- terms: [BLA / NDA / MAA (marketing applications) and PDUFA dates](https://onco.cc/terms/bla-nda/), [Clinical trial search, site verification and screening](https://onco.cc/terms/trial-search-site-verification/), [Expanded access (compassionate use)](https://onco.cc/terms/expanded-access/), [Fast Track and RMAT designations](https://onco.cc/terms/fast-track-rmat/), [First-in-human (FIH) trial](https://onco.cc/terms/first-in-human/), [Investigator-initiated trials and study responsibilities](https://onco.cc/terms/investigator-initiated-trials/), [Label, indication and label expansion](https://onco.cc/terms/label-indication/), [Off-label](https://onco.cc/terms/off-label/), [Right to Try Act 2018 and state right-to-try laws](https://onco.cc/terms/right-to-try/), [Trial protocol and statistical analysis plan](https://onco.cc/terms/trial-protocol/)

---
JSON: https://onco.cc/api/v1/entities/investigational-new-drug-application.json